Roundhill Investmentslaunched a new exchange-traded fund (ETF) Tuesday.

What Happened: TheRoundhill GLP-1 & Weight Loss ETF(NASDAQ:OZEM) marks a significant milestone as the world's first GLP-1 ETF.

Roundhill asserts that weight loss drugs, particularly GLP-1 agonists, are among the most revolutionary advancements in the global pharmaceuticals industry.

Notably, OZEM is the only ETF providing dedicated exposure to transformative weight loss stocks such asEli Lilly & Co.(NYSE:LLY), the producer of Zepbound, andNovo Nordisk A/S(NYSE:NVO), the maker of Ozempic.

"These new treatments work incredibly well," Roundhill CEODave Mazzatold Benzinga.

Citing...